Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Innoviva Inc (NASDAQ:INVA)

11.38
Delayed Data
As of Aug 26
 +0.17 / +1.52%
Today’s Change
6.36
Today|||52-Week Range
16.62
+7.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.3B

Company Description

Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Contact Information

Innoviva, Inc.
901 Gateway Boulevard
South San Francisco California 94080
P:(650) 238-9600
Investor Relations:

Employees

Shareholders

Other institutional45.35%
Mutual fund holders35.02%
Individual stakeholders1.52%

Top Executives

Michael W. AguiarPresident, Chief Executive Officer & Director
Eric d'EsparbesChief Financial Officer & Senior Vice President
Theodore L. WitekChief Scientific Officer & Senior Vice President
George B. AbercrombieChief Commercial Officer & Senior Vice President
Michael E. FaermChief Business Officer & Senior Vice President